HighTower Advisors LLC cut its holdings in Astrazeneca PLC (NYSE:AZN) by 27.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 136,427 shares of the company’s stock after selling 51,042 shares during the period. HighTower Advisors LLC’s holdings in Astrazeneca PLC were worth $4,640,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of AZN. Meeder Asset Management Inc. acquired a new position in shares of Astrazeneca PLC during the 2nd quarter valued at about $105,000. Salem Investment Counselors Inc. acquired a new stake in shares of Astrazeneca PLC in the first quarter worth approximately $107,000. Tower Research Capital LLC TRC boosted its position in shares of Astrazeneca PLC by 3,782.0% in the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after acquiring an additional 3,782 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of Astrazeneca PLC by 27.1% in the first quarter. Parallel Advisors LLC now owns 4,526 shares of the company’s stock worth $138,000 after acquiring an additional 964 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. boosted its position in shares of Astrazeneca PLC by 71.2% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock worth $145,000 after acquiring an additional 1,769 shares during the last quarter. Institutional investors own 14.17% of the company’s stock.

A number of research firms have weighed in on AZN. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, August 9th. BidaskClub cut shares of Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a research note on Friday, August 4th. Investec upgraded Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Cowen and Company restated a “hold” rating and set a $34.00 price objective on shares of Astrazeneca PLC in a report on Friday, July 28th. Finally, BNP Paribas raised Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a research report on Monday, September 25th. Four research analysts have rated the stock with a sell rating, eleven have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $34.20.

Astrazeneca PLC (NYSE AZN) opened at 34.26 on Wednesday. The company has a 50-day moving average price of $31.44 and a 200-day moving average price of $32.08. The stock has a market cap of $86.75 billion, a P/E ratio of 22.47 and a beta of 0.76. Astrazeneca PLC has a one year low of $25.55 and a one year high of $35.60.

Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same period in the prior year, the firm earned $0.83 EPS. Astrazeneca PLC’s quarterly revenue was down 9.9% compared to the same quarter last year. On average, analysts anticipate that Astrazeneca PLC will post $1.91 earnings per share for the current year.

The company also recently announced a None dividend, which was paid on Monday, September 11th. Shareholders of record on Friday, August 11th were given a dividend of $0.44 per share. This represents a yield of 2.98%. The ex-dividend date was Wednesday, August 9th. Astrazeneca PLC’s dividend payout ratio is 44.92%.

TRADEMARK VIOLATION NOTICE: “Astrazeneca PLC (AZN) Holdings Reduced by HighTower Advisors LLC” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/04/astrazeneca-plc-azn-holdings-reduced-by-hightower-advisors-llc.html.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.